Cell Therapeutics (CTIC) has signed a worldwide licensing deal with Norvartis worth US$285M. This agreement will see Norvatis assisting in the development and commercialisation of Cell Therapeutics’ flagship drug, XYOTAX. The amount includes US$15M equity investment in the drug development company as well.
Cell Therapeutics traded up 13 cents or 6.67% on Monday to $2.08.
- Cell Therapeutics to Submit New XYOTAX Drug Trial to FDA
- Cell Therapeutics To Suspend Enrollment for PIONEER Drug Trial
- Cell Therapeutics Up After Positive Xyotax Phase 1 Results